Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Trillium Therapeutics stock | $11.78

Own Trillium Therapeutics stock in just a few minutes.

Fact checked

Trillium Therapeutics Inc is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Trillium Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Trillium Therapeutics. Find the stock by name or ticker symbol: TRIL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Trillium Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$11.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Trillium Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Trillium Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Trillium Therapeutics share price

Use our graph to track the performance of TRIL stocks over time.

Trillium Therapeutics shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$11.78
52-week rangeUSD$0.29 - USD$20.96
50-day moving average USD$14.9771
200-day moving average USD$11.0229
Wall St. target priceUSD$11.02
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.548

Buy Trillium Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Trillium Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trillium Therapeutics price performance over time

Historical closes compared with the close of $11.78 from 2020-12-09

1 week (2021-01-13) N/A
1 month (2020-12-24) -9.52%
3 months (2020-10-20) N/A
6 months (2020-07-20) N/A
1 year (2020-01-20) N/A
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

Trillium Therapeutics financials

Revenue TTM USD$115,000
Gross profit TTM USD$124,000
Return on assets TTM -19.01%
Return on equity TTM -189.45%
Profit margin 0%
Book value $1.642
Market capitalisation USD$1.8 billion

TTM: trailing 12 months

Shorting Trillium Therapeutics shares

There are currently 5.9 million Trillium Therapeutics shares held short by investors – that's known as Trillium Therapeutics's "short interest". This figure is 53.9% up from 3.9 million last month.

There are a few different ways that this level of interest in shorting Trillium Therapeutics shares can be evaluated.

Trillium Therapeutics's "short interest ratio" (SIR)

Trillium Therapeutics's "short interest ratio" (SIR) is the quantity of Trillium Therapeutics shares currently shorted divided by the average quantity of Trillium Therapeutics shares traded daily (recently around 1.2 million). Trillium Therapeutics's SIR currently stands at 4.78. In other words for every 100,000 Trillium Therapeutics shares traded daily on the market, roughly 4780 shares are currently held short.

However Trillium Therapeutics's short interest can also be evaluated against the total number of Trillium Therapeutics shares, or, against the total number of tradable Trillium Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trillium Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Trillium Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0604% of the tradable shares (for every 100,000 tradable Trillium Therapeutics shares, roughly 60 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trillium Therapeutics.

Find out more about how you can short Trillium Therapeutics stock.

Trillium Therapeutics share dividends

We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.

Have Trillium Therapeutics's shares ever split?

Trillium Therapeutics's shares were split on a 1:30 basis on 20 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.

Trillium Therapeutics share price volatility

Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $0.29 up to $20.96. A popular way to gauge a stock's volatility is its "beta".

TRIL.US volatility(beta: 2.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 2.2307. This would suggest that Trillium Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Trillium Therapeutics overview

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site